GreenLight Biosciences Holdings PBC

GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. Its breakthrough biomanufacturing platform is engaged in discovering, developing, scaling, and commercializing RNA solutions at volume across multiple sectors in the agricultural and human health markets. The company is headquartered in Medford, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. Its breakthrough biomanufacturing platform is engaged in discovering, developing, scaling, and commercializing RNA solutions at volume across multiple sectors in the agricultural and human health markets. The company is headquartered in Lexington, MA.

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the “NASDAQ”) before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each remaining share of GreenLight common stock not purchased in the Offer (other than shares of GreenLight common stock (i) owned by GreenLight as treasury stock, (ii) owned by Merger Sub immediately before the effective time of the Merger, (iii) that were irrevocably accepted by Merger Sub in the Offer, (iv) held by stockholders who have perfected their statutory rights of appraisal under Section 262 of the DGCL or (v) that are subject to the Contribution and Exchange Agreements entered into between Parent and certain stockholders of GreenLight) will be converted into the right to receive $0.30 in cash, without interest, and subject to deduction for any required withholding taxes.

GreenLight Announces Completion of Merger with Fall Line Endurance Fund

Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023 Completion of Previously Announced Merger and Going Private Transaction Expected July 20, 2023

GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

Environmental Impact Acquisition Corp

PHILADELPHIA , June 15, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating GreenLight Biosciences Holdings (NASDAQ: GRNA) ("GreenLight") on behalf of the company's long-term shareholders. GreenLight operates as a pre-commercial stage biotechnology company in the United States.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of GreenLight Biosciences Holdings and Encourages Long-Term GRNA / ENVI Shareholders to Contact the Firm

NEW YORK , June 5, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who hold Greenlight Biosciences Holdings PBC ("GRNA" or the "Company") (NASDAQ: GRNA) stock. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into potential breaches of fiduciary duty by the GRNA board of directors.

GRNA ALERT: Levi & Korsinsky, LLP Announces an Investigation of Greenlight Biosciences

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GreenLight Biosciences Holdings, PBC (NasdaqGM: GRNA) to a consortium led by Fall Line Capital, LLC. Under the terms of the proposed transaction, shareholders of GreenLight will receive $0.30 in cash for each share of GreenLight that they own. KSF is seeking to determine whether this consideration and the proc.

GREENLIGHT BIOSCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GreenLight Biosciences Holdings, PBC - GRNA

MILWAUKEE , May 30, 2023 /PRNewswire/ -- Ademi LLP is investigating GreenLight (NASDAQ: GRNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Fall Line.  Click here to learn how to join the action https://www.ademilaw.com/case/greenlight-biosciences-holdings-pbc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether GreenLight Biosciences Holdings, PBC has obtained a Fair Price in its transaction with Fall Line

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) to a group of buyers led by Fall Line Capital, LLC for $0.30 per share is fair to GreenLight shareholders. Halper Sadeh encourages GreenLight shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The.

GRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of GreenLight Biosciences Holdings, PBC Is Fair to Shareholders

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.

GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today released its inaugural Sustainability Report.

GreenLight Biosciences Releases Inaugural Sustainability Report

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA) (“GreenLight” or the “Company”), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today, confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. (“Fall Line”) to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash (the “Proposed Transaction”). The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction.

GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today reported operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results

-- Progressing human health pipeline conferring mRNA platform advantages for infectious disease and personalized oncology medicines; pursuing capital efficient strategy targeting unmet medical needs, in both the developed and lower- and middle-income countries (LMICs), pairing focused R&D spend with partnerships

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, will today outline its pipeline strategy and R&D progress for dsRNA based crop protection and plant delivery innovations focused on addressing food security with innovative and sustainable solutions during its Plant Health R&D Day being held today, March 7th, 2023 at 10:30 a.m. ET in Research Triangle, North Carolina.

GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced it will host a two-part R&D Day Series for analysts and investors.

GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy

KIGALI, Rwanda and Lexington, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.

GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate

BOSTON and PROVIDENCE, R.I., Jan. 09, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.

GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

The company reportedly turned down offers to go private.

Why Greenlight Biosciences Stock Was in the Red Today

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today reported operational highlights and financial results for the third quarter ended September 30, 2022.

GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world's toughest problems in human health and agriculture, today announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.

GreenLight Biosciences to Participate in Upcoming Investor Conferences in November

GreenLight Biosciences Holdings GRNA, -1.44% said Wednesday that it was laying off 25% of its workforce as part of a “realignment” aimed at saving cash as it shifts its focus to near-term value drivers. The biotechnology company had 312 full-time employees as of March 31.

GreenLight Biosciences to cut 25% of its workforce as part of ‘realignment' to extend cash runway

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term value drivers and extend its cash runway.

GreenLight Biosciences announces realignment to focus on near-term value drivers

BOSTON and BRISBANE, Australia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Researchers from Boston's GreenLight Biosciences and the  Queensland University of Technology (QUT) in Brisbane, Australia, have announced an agreement to develop a solution to fall armyworm, which causes more than US$2 billion in annual global crop loss.

GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA

Nextdoor

BitNile Holdings

Protara Therapeutics Inc

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person in our planet, today reported operational highlights and financial results for the second quarter ended June 30, 2022.

News for GreenLight Biosciences Holdings PBC Stock (GRNA)